Trial Profile
A Phase II Study Of Sunitinib Malate Single Agent For The Treatment Of Women With Advanced Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2011
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 03 Aug 2010 Actual end date (1 Jun 2010) added as reported by ClinicalTrials.gov.
- 03 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.